Remove Biosimilars Remove Generic Medicine Remove Pharmaceutical Manufacturing Related Topics
article thumbnail

Omnibus Spending Law: Provisions Will Bolster Medicines Supply Chain Insights and Advanced Manufacturing Technologies

Quality Matters

Leveraging insights from data on USP standards distribution and usage at more than 22,000 locations worldwide and 40+ external data sets, USP launched the Medicine Supply Map in 2021 to provide an early-warning capability for supply chain vulnerabilities. Such products include small molecule medicines, biologics and biosimilars.